Ibrutinib treatment improves T cell number and function in CLL patients
Ibrutinib treatment improves T cell number and function in CLL patients
About this item
Full title
Author / Creator
Long, Meixiao , Beckwith, Kyle , Do, Priscilla , Mundy, Bethany L. , Gordon, Amber , Lehman, Amy M. , Maddocks, Kami J. , Cheney, Carolyn , Jones, Jeffrey A. , Flynn, Joseph M. , Andritsos, Leslie A. , Awan, Farrukh , Fraietta, Joseph A. , June, Carl H. , Maus, Marcela V. , Woyach, Jennifer A. , Caligiuri, Michael A. , Johnson, Amy J. , Muthusamy, Natarajan and Byrd, John C.
Publisher
United States: American Society for Clinical Investigation
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Society for Clinical Investigation
Subjects
More information
Scope and Contents
Contents
Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies.
Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) pati...
Alternative Titles
Full title
Ibrutinib treatment improves T cell number and function in CLL patients
Authors, Artists and Contributors
Author / Creator
Beckwith, Kyle
Do, Priscilla
Mundy, Bethany L.
Gordon, Amber
Lehman, Amy M.
Maddocks, Kami J.
Cheney, Carolyn
Jones, Jeffrey A.
Flynn, Joseph M.
Andritsos, Leslie A.
Awan, Farrukh
Fraietta, Joseph A.
June, Carl H.
Maus, Marcela V.
Woyach, Jennifer A.
Caligiuri, Michael A.
Johnson, Amy J.
Muthusamy, Natarajan
Byrd, John C.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5531425
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5531425
Other Identifiers
ISSN
0021-9738
E-ISSN
1558-8238
DOI
10.1172/JCI89756
